This drug class confers benefits in diabetic patients with heart failure, CV disease, and renal disease, but it is also associated with major adverse events.
According to the CDC’s Behavioral Risk Factor Surveillance System 2013, nearly 71% of adults with atherosclerotic cardiovascular disease use aspirin regularly.
Prescribing low-dose aspirin for preventing secondary cardiovascular disease is well established, but its safety and efficacy in primary prevention remains open to debate.